A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2015
At a glance
- Drugs CNTO 6785 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 07 Jun 2017 Biomarkers information updated
- 23 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jun 2015.